ANTIBIOTIC THERAPY FAILURE AND THE RISING CHALLENGE OF ANTIMICROBIAL RESISTANCE IN PEDIATRIC PNEUMONIA PATIENTS IN KHYBER PAKHTUNKHWA PAKISTAN
Main Article Content
Keywords
Antimicrobial resistance (AMR), Antibiotic, Therapy failure, Switching-over, Pediatric pneumonia
Abstract
Background: Drug-resistant bacterial strains cause various infections including pneumonia, which then go unchecked, as the prevalence of culture and sensitivity tests are not entertained before planning therapy. The current study aimed to evaluate the prescribing practices of antibiotics, therapy failure, and to assess the patient response. Therapy failure and antibiotic switching-over are a sign of drug-resistance and possibly antimicrobial resistance (AMR).
Methods: A total of n=60 pediatric pneumonia cases were collected and evaluated for prescription pattern of antibiotics, hospital longevity, overall antibiotic consumption, switching-over and patient discharge assessment, respectively.
Results: The study results showed that pneumonia is more common in children (1-5 years); n=24 (40%), followed by neonates (0-12 months); n= 19 (31.6%), respectively. Monotherapy was used upon initial admission of patients, while combination therapy and antibiotic switching-over were noticed when patients were not responding to initial antibiotic therapy. Due to non-responsiveness, the patient’s hospital stay was prolonged and antibiotic regimens were switched over indicating the possibility of drug-resistant bacterial strains. Next, upon utilization of monotherapy (single antibiotic), the average hospital stay was 6.5 days, while 3.5 days with combination therapy (two antibiotics). The total number of antibiotics were 122 with highest number prescriptions of cefoperazone (n=35, 28.6%), meropenem (n=31, 25.4%), and vancomycin and linezolid both having n=24 (19.6%) for each. The most commonly used regimens were meropenem+linezolid (n=9), meropenem+vancomycin (n=7) followed by cefoperazone+linezolid and cefoperazone+vancomycin both having n=5, respectively. Switching-over was noted mostly for monotherapy drugs cefoperazone (15 times), followed by ampicillin, ceftriaxone and meropenem (2 times), respectively. Furthermore, meropenem+linezolid reflected as the best combination with patient discharge n=10 with 16.6% and hospital longevity less than 2 days.
Conclusion: This study highlights the emerging silent pandemic of drug-resistant bacterial strains responsible for causing pneumonia in pediatric patients. This trend may be perceived as a sign of AMR, and needs careful watch and reporting. We recommend further studies on provincial and national level hospitals to prevent the upcoming health concern and its worse consequences.
References
2. Laxminarayan R, Matsoso P, Pant S, Brower C, Røttingen J-A, Klugman K, Davies S: Access to effective antimicrobials: a worldwide challenge. The Lancet 2016, 387:168-175.
3. Fadel SA, Boschi-Pinto C, Yu S, Reynales-Shigematsu LM, Menon GR, Newcombe L, Strong KL, Wang Q, Jha P: Trends in cause-specific mortality among children aged 5–14 years from 2005 to 2016 in India, China, Brazil, and Mexico: an analysis of nationally representative mortality studies. The Lancet 2019, 393:1119-1127.
4. Mackenzie G: The definition and classification of pneumonia. Pneumonia 2016, 8:1-5.
5. Troeger CE, Khalil IA, Blacker BF, Biehl MH, Albertson SB, Zimsen SR, Rao PC, Abate D, Admasie A, Ahmadi A: Quantifying risks and interventions that have affected the burden of lower respiratory infections among children younger than 5 years: an analysis for the Global Burden of Disease Study 2017. The Lancet infectious diseases 2020, 20:60-79.
6. Hung IF-N, Tantawichien T, Tsai YH, Patil S, Zotomayor R: Regional epidemiology of invasive pneumococcal disease in Asian adults: epidemiology, disease burden, serotype distribution, and antimicrobial resistance patterns and prevention. International Journal of Infectious Diseases 2013, 17:e364-e373.
7. Ahmed S, Ariff S, Muhammed S, Rizvi A, Ahmed I, Soofi SB, Bhutta ZA: Community case management of fast-breathing pneumonia with 3 days oral amoxicillin vs 5 days cotrimoxazole in children 2-59 months of age in rural Pakistan: A cluster randomized trial. Journal of Global Health 2022, 12.
8. Rothman KJ: Epidemiology: an introduction. Oxford university press; 2012.
9. Morrison L, Zembower TRJGEC: Antimicrobial resistance. 2020, 30:619-635.
10. Hayat K, Jamshed S, Rosenthal M, Haq NU, Chang J, Rasool MF, Malik UR, Rehman AU, Khan KM, Fang YJA: Understanding of Pharmacy Students towards Antibiotic Use, Antibiotic Resistance and Antibiotic Stewardship Programs: A Cross-Sectional Study from Punjab, Pakistan. 2021, 10:66.
11. Chokshi A, Sifri Z, Cennimo D, Horng HJJogid: Global contributors to antibiotic resistance. 2019, 11:36.
12. Chua AQ, Verma M, Hsu LY, Legido-Quigley HJTLRH-WP: An analysis of national action plans on antimicrobial resistance in Southeast Asia using a governance framework approach. 2021, 7:100084.
13. Laxminarayan R, Van Boeckel T, Frost I, Kariuki S, Khan EA, Limmathurotsakul D, Larsson DJ, Levy-Hara G, Mendelson M, Outterson KJTLID: The Lancet Infectious Diseases Commission on antimicrobial resistance: 6 years later. 2020, 20:e51-e60.
14. Shanbhag TV, Shenoy S, Nayak V: Pharmacology for Dentistry E-Book. Elsevier Health Sciences; 2021.
15. Sulis G, Sayood S, Gandra S: How can we tackle the overuse of antibiotics in low-and middle-income countries? Expert Review of Anti-infective Therapy 2023.
16. !!! INVALID CITATION !!! (Hays et al., 2022; Kariuki et al., 2023; Soper et al., 2022).
17. Tattevin P, Levy Hara G, Toumi A, Enani M, Coombs G, Voss A, Wertheim H, Poda A, Daoud Z, Laxminarayan R: Advocacy for increased international efforts for antimicrobial stewardship actions in low-and middle-Income countries on behalf of alliance for the Prudent Use of Antimicrobials (APUA), under the auspices of the International Society of Antimicrobial Chemotherapy (ISAC). Frontiers in Medicine 2020, 7:503.
18. Fostira E, Bitsori M, Vergadi E, Maraki S, Galanakis E: Short‐term antibiotic exposure affected the type and resistance of uropathogens similar to long‐term antibiotic prophylaxis in children hospitalised for urinary tract infections. Acta Paediatrica 2020, 109:1260-1266.
19. Sharma A, Singh A, Dar MA, Kaur RJ, Charan J, Iskandar K, Haque M, Murti K, Ravichandiran V, Dhingra S: Menace of antimicrobial resistance in LMICs: Current surveillance practices and control measures to tackle hostility. Journal of Infection and Public Health 2022, 15:172-181.
20. Mir F, Ariff S, Bhura M, Chanar S, Nathwani AA, Jawwad M, Hussain A, Rizvi A, Umer M, Memon Z: Risk factors for acute respiratory infections in children between 0 and 23 months of age in a peri-urban district in Pakistan: A matched case–control study. Frontiers in pediatrics 2022, 9:704545.
21. Lee JS, Giesler DL, Gellad WF, Fine MJ: Antibiotic therapy for adults hospitalized with community-acquired pneumonia: a systematic review. Jama 2016, 315:593-602.
22. Paul M, Carrara E, Retamar P, Tängdén T, Bitterman R, Bonomo RA, De Waele J, Daikos GL, Akova M, Harbarth S: European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine). Clinical Microbiology and Infection 2022, 28:521-547.
23. Khatavkar P, Gulrukh W, Dawane JS, Shreyas D, Pandit V: Understanding about antibiotics and its usage in the community-A pilot study. Health 2021, 40:80.
24. Sano M, Shindo Y, Takahashi K, Okumura J, Sakakibara T, Murakami Y, Iguchi M, Yagi T, Matsui S, Hasegawa Y: Risk factors for antibiotic resistance in hospital-acquired and ventilator-associated pneumonia. Journal of Infection and Chemotherapy 2022, 28:745-752.
25. Al-Madboly LA: A Novel Triple Combination to Combat Serious Infections with Carbapenem-Resistant Acinetobacter baumannii in a Mouse Pneumonia Model. Microbiology Spectrum 2022, 10:e02710-02721.
26. Ramadan RA, Bedawy AM, Negm EM, Hassan TH, Ibrahim DA, ElSheikh SM, Amer RM: Carbapenem-resistant Klebsiella pneumoniae among patients with ventilator-associated pneumonia: Evaluation of antibiotic combinations and susceptibility to new antibiotics. Infection and Drug Resistance 2022:3537-3548.
27. Foucrier A, Dessalle T, Tuffet S, Federici L, Dahyot‑Fizelier C, Barbier F, Pottecher J, Monsel A, Hissem T, Lefrant JY: Association between combination antibiotic therapy as opposed as monotherapy and outcomes of ICU patients with Pseudomonas aeruginosa ventilator-associated pneumonia: an ancillary study of the iDIAPASON trial. Critical Care 2023, 27:211.
28. Onorato L, Macera M, Calò F, Cirillo P, Di Caprio G, Coppola N: Beta-lactam monotherapy or combination therapy for bloodstream infections or pneumonia due to Pseudomonas aeruginosa: A meta-analysis. International Journal of Antimicrobial Agents 2022, 59:106512.
29. Jones F, Hu Y, Coates A: The efficacy of using combination therapy against multi-drug and extensively drug-resistant Pseudomonas aeruginosa in clinical settings. Antibiotics 2022, 11:323.
30. Shah H, Bibi U, Kamal Z, Esa M, Naeem M, Ahmad S, Shafique M: Prescribing Pattern of Ampicillin and Cloxacillin: Sensitivity and Responsiveness in Pneumonia: Antibiotic resistance. Proceedings of the Pakistan Academy of Sciences: B Life and Environmental Sciences 2023, 60:65-75.
31. Roh EJ, Lee M-H, Lee JY, Kim H-B, Ahn YM, Kim JK, Kim HY, Jung S-S, Kim M, Kang EK: Analysis of national surveillance of respiratory pathogens for community-acquired pneumonia in children and adolescents. BMC Infectious Diseases 2022, 22:330.
32. Assefa M, Amare A: Biofilm-Associated multi-drug resistance in hospital-acquired infections: a review. Infection and Drug Resistance 2022:5061-5068.
33. Poudel AN, Zhu S, Cooper N, Little P, Tarrant C, Hickman M, Yao G: The economic burden of antibiotic resistance: A systematic review and meta-analysis. Plos one 2023, 18:e0285170.
34. Salam MA, Al-Amin MY, Salam MT, Pawar JS, Akhter N, Rabaan AA, Alqumber MA: Antimicrobial resistance: A growing serious threat for global public health. In Healthcare. MDPI; 2023: 1946.
35. Assefa M: Multi-drug resistant gram-negative bacterial pneumonia: etiology, risk factors, and drug resistance patterns. Pneumonia 2022, 14:4.
36. LaPlante KL, Dhand A, Wright K, Lauterio M: Re-establishing the utility of tetracycline-class antibiotics for current challenges with antibiotic resistance. Annals of Medicine 2022, 54:1686-1700.
37. Bassetti S, Tschudin-Sutter S, Egli A, Osthoff M: Optimizing antibiotic therapies to reduce the risk of bacterial resistance. European journal of internal medicine 2022, 99:7-12.
38. Nimer NA: Nosocomial infection and antibiotic-resistant threat in the Middle East. Infection and drug resistance 2022:631-639.
39. Agyeman WY, Bisht A, Gopinath A, Cheema AH, Chaludiya K, Khalid M, Nwosu M, Konka S, Khan S: A systematic review of antibiotic resistance trends and treatment options for hospital-acquired multidrug-resistant infections. Cureus 2022, 14.
40. Sharma A, Thakur A, Thakur N, Kumar V, Chauhan A, Bhardwaj N, Thakur Sr A: Changing trend in the antibiotic resistance pattern of Klebsiella pneumonia isolated from endotracheal aspirate samples of ICU patients of a tertiary care hospital in north India. Cureus 2023, 15.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Muhammad Esa
Drug Delivery System Excellence Center, Department of Pharmaceutical Technology, Faculty of Pharmaceutical Sciences, Prince of Songkla University, Hat Yai, Songkhla 90110, Thailand
Rabia Iqbal
Cadson College of Pharmacy, Kharian, University of the Punjab, Lahore, Punjab, Pakistan.
Irfan Hamid
Cadson College of Pharmacy, Kharian, University of the Punjab, Lahore, Punjab, Pakistan.
Kashif Sohail
Akson College of Pharmacy, Mirpur University of Science & Technology (MUST), Mirpur, AJK, Pakistan.
Zeeshan Javaid
Department of Pharmacy, Mirpur University of Science & Technology (MUST), Mirpur, AJK, Pakistan.
Zul Kamal
School of Pharmacy, Shanghai Jiao Tong University, China
Asad Ur Rahman
Department of Pharmacognosy and Pharmaceutical Botany, Prince of Songkla University, Hat Yai, Songkhla 90110, Thailand
Muhammad Abbas Amanat
Department of Preventive Dentistry, Faculty of Dentistry, Prince of Songkla University, Songkhla, Thailand
Kashif Ali Khan
Department of Pharmacy, Shaheed Benazir Bhutto University Sheringal Dir Upper, 18200, Khyber Pakhtunkhwa, Pakistan.
Bashir Ullah
Department of Pharmacy, Shaheed Benazir Bhutto University Sheringal Dir Upper, 18200, Khyber Pakhtunkhwa, Pakistan.